Ozmosi | Pizotifen Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Pizotifen

Alternative Names: pizotifen
Clinical Status: Inactive
Latest Update: 2025-10-01
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT2A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | Bangladesh | Brazil | Canada | Chile | Cyprus | Denmark | France | Hong Kong | Iceland | Ireland | Italy | Jordan | Lebanon | Malaysia | New Zealand | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Turkey | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title